These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 26625211)

  • 1. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
    Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
    Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SLFN11 and ATR as targets for overcoming cisplatin resistance in ovarian cancer cells.
    König P; Eichhorn JM; Suparman E; Bückreiß N; Cinatl J; Michaelis M; Bendas G
    Biochim Biophys Acta Mol Basis Dis; 2024 Dec; 1870(8):167448. PubMed ID: 39117290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
    Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
    Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel.
    Shen L; Kondo Y; Ahmed S; Boumber Y; Konishi K; Guo Y; Chen X; Vilaythong JN; Issa JP
    Cancer Res; 2007 Dec; 67(23):11335-43. PubMed ID: 18056460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer.
    He T; Zhang M; Zheng R; Zheng S; Linghu E; Herman JG; Guo M
    Epigenomics; 2017 Jun; 9(6):849-862. PubMed ID: 28403629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.
    Taniyama D; Sakamoto N; Takashima T; Takeda M; Pham QT; Ukai S; Maruyama R; Harada K; Babasaki T; Sekino Y; Hayashi T; Sentani K; Pommier Y; Murai J; Yasui W
    Cancer Sci; 2022 Feb; 113(2):784-795. PubMed ID: 34808009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.
    Bonito NA; Borley J; Wilhelm-Benartzi CS; Ghaem-Maghami S; Brown R
    Clin Cancer Res; 2016 Jun; 22(12):3097-3104. PubMed ID: 26763252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.
    Stefansson OA; Villanueva A; Vidal A; Martí L; Esteller M
    Epigenetics; 2012 Nov; 7(11):1225-9. PubMed ID: 23069641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer.
    Winkler C; King M; Berthe J; Ferraioli D; Garuti A; Grillo F; Rodriguez-Canales J; Ferrando L; Chopin N; Ray-Coquard I; Delpuech O; Rinchai D; Bedognetti D; Ballestrero A; Leo E; Zoppoli G
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (
    Tang SW; Thomas A; Murai J; Trepel JB; Bates SE; Rajapakse VN; Pommier Y
    Clin Cancer Res; 2018 Apr; 24(8):1944-1953. PubMed ID: 29391350
    [No Abstract]   [Full Text] [Related]  

  • 11. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
    Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
    Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel PARP4 gene promoter CpG locus associated with cisplatin chemoresistance.
    Sung HY; Han J; Chae YJ; Ju W; Lee Kang J; Park AK; Ahn JH
    BMB Rep; 2023 Jun; 56(6):347-352. PubMed ID: 37013346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
    Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
    Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
    Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
    Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.
    Syed N; Coley HM; Sehouli J; Koensgen D; Mustea A; Szlosarek P; McNeish I; Blagden SP; Schmid P; Lovell DP; Hatzimichael E; Crook T
    Cancer Res; 2011 May; 71(9):3317-27. PubMed ID: 21402713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An epigenomic approach to identifying differential overlapping and cis-acting lncRNAs in cisplatin-resistant cancer cells.
    Vera O; Rodriguez-Antolin C; de Castro J; Karreth FA; Sellers TA; Ibanez de Caceres I
    Epigenetics; 2018; 13(3):251-263. PubMed ID: 29436261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
    Nicholson LJ; Smith PR; Hiller L; Szlosarek PW; Kimberley C; Sehouli J; Koensgen D; Mustea A; Schmid P; Crook T
    Int J Cancer; 2009 Sep; 125(6):1454-63. PubMed ID: 19533750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer.
    Oguri T; Isobe T; Suzuki T; Nishio K; Fujiwara Y; Katoh O; Yamakido M
    Int J Cancer; 2000 Apr; 86(1):95-100. PubMed ID: 10728601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq.
    Takashima T; Sakamoto N; Murai J; Taniyama D; Honma R; Ukai S; Maruyama R; Kuraoka K; Rajapakse VN; Pommier Y; Yasui W
    Virchows Arch; 2021 Mar; 478(3):569-579. PubMed ID: 32474729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.